December 7, 2015

Kite Pharma Initiates the ZUMA-4 Study to Support Registration of KTE-C19 for Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) in Children and Young Adults

December 3, 2015

Kite Pharma and GE Global Research Announce Strategic Collaboration to Automate Manufacturing of Engineered T Cell Therapies

December 2, 2015

Kite Pharma Initiates the ZUMA-3 Study to Support Registration of KTE-C19 for Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) in Adult Subjects

November 24, 2015

Capricor Therapeutics to Present at the 2015 Piper Jaffray Healthcare Conference

November 16, 2015

Arno Therapeutics Reports Third Quarter 2015 Financial Results and Business Update

November 12, 2015

Capricor Therapeutics Reports Third Quarter 2015 Business & Financial Highlights

November 12, 2015

Kite Pharma Reports Third Quarter 2015 Financial Results and Provides Business Update

November 9, 2015

Capricor Therapeutics Presents Positive Data from the DYNAMIC Clinical Trial at 2015 American Heart Association Scientific Sessions

November 9, 2015

Kite Pharma Initiates Phase 2 Clinical Study of KTE-C19 (ZUMA-2) in Patients With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) to Support Registration for a Second Indication

November 6, 2015

Capricor Therapeutics To Present Data from the DYNAMIC Clinical Trial at American Heart Association Scientific Sessions 2015

November 5, 2015

Capricor Therapeutics To Present Data from the DYNAMIC Clinical Trial at American Heart Association Scientific Sessions 2015

November 5, 2015

Kite Pharma to Present Four Abstracts, including Safety and Efficacy Data from the KTE-C19 Phase 1 Study in Patients with Refractory, Aggressive NHL (ZUMA-1), at the 57th American Society of Hematology Annual Meeting (ASH)

November 4, 2015

Kite Pharma to Present at Upcoming Investor Conferences in November 2015

November 4, 2015

Capricor Therapeutics to Hold Third Quarter 2015 Business Update and Financial Results Conference Call on November 12, 2015 at 4:30 p.m. EST

October 29, 2015

Capricor Therapeutics and CureDuchenne to Host Webinar on November 3, 2015 at 3:00 p.m. ET

October 29, 2015

Kite Pharma and Alpine Immune Sciences Announce Research Collaboration and License Agreement to Enhance Immune Response in the Tumor Microenvironment

October 27, 2015

Kite Pharma Initiates ZUMA-1 Phase 2 in Patients With Aggressive, Refractory Non-Hodgkin’s Lymphoma (NHL) to Support Registration of KTE-C19

October 27, 2015

Kite Pharma and Alpine Immune Sciences Announce Research Collaboration and License Agreement to Enhance Immune Response in the Tumor Microenvironment

October 21, 2015

Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains

October 15, 2015

Kite Pharma Announces Exclusive License with the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat Tumors Expressing MAGE

October 15, 2015

Kite Pharma Receives Positive Opinions for Orphan Drug Designation in the European Union (EU) for KTE-C19 in Three Additional Hematological Indications

October 7, 2015

Kite Pharma Commends Steven A. Rosenberg, M.D., Ph.D., on the Prestigious Medal of Honor Award From the American Cancer Society

October 1, 2015

Kite Pharma Announces Peer-Reviewed Publication of T Cell Receptor Based Product Candidate to Treat HPV-Associated Cancers

September 30, 2015

Capricor Therapeutics to Present at 2015 Stem Cell Meeting on the Mesa

September 25, 2015

Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference